10-Q · May 12, 2026
Savara Inc. reported a significant net loss of $37.3 million for Q1 2026, compared to a loss of $26.6 million in Q1 2025. Operating expenses rose by 37.2% year-over-year due to increased R&D and G&A costs. The company's…
Earnings analysis · 10-Q
SVRA earnings analysis
Filed August 11, 2026 · Our reading of the company's report
The latest report
Savara remains a pre-revenue, single-program biotech with no disclosed revenue, a second-quarter net loss of $40.2 million and six-month operating cash use of $62.8 million. Liquidity was approximately $173.0 million at…
Read full summary
Savara remains a pre-revenue, single-program biotech with no disclosed revenue, a second-quarter net loss of $40.2 million and six-month operating cash use of $62.8 million. Liquidity was approximately $173.0 million at June 30, 2026, but management expects continued losses and may need additional capital. Regulatory progress for MOLBREEVI is constructive, although the FDA extended the PDUFA date to November 22, 2026, preserving substantial approval and commercialization risk.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Segment
- Single operating segment; no product revenue has been generated from inception through June 30, 2026
What stood out
-
MOLBREEVI remains under priority review
The FDA formally filed the MOLBREEVI BLA and granted Priority Review in February 2026; the FDA subsequently extended the PDUFA target action date by three months to November 22, 2026.
-
$173.0M liquidity position
Cash, cash equivalents and short-term investments totaled approximately $173.0 million at June 30, 2026, including $41.8 million of cash and cash equivalents and $131.2 million of short-term investments.
-
Investments offset operating cash burn
Six-month cash used in operating activities was $62.8 million, while investing activities provided $71.4 million, primarily from maturities and activity in short-term investments; net cash increased by $8.6 million.
-
Commercial launch infrastructure advancing
Management is building commercial infrastructure ahead of a planned product launch: second-quarter G&A expense increased 78.2% year over year to $19.0 million, including $7.5 million of higher personnel costs.
-
European regulatory submissions validated
MOLBREEVI submissions have also advanced in Europe and the U.K.; the EMA validated the MAA in March 2026 and the MHRA validated the U.K. MAA in April 2026 with a 150-day accelerated assessment.
What to watch
-
Losses continue to widen
Second-quarter net loss increased to $40.2 million from $30.4 million in the prior-year quarter, while six-month net loss reached $77.5 million versus $57.0 million in the prior-year period.
-
Rising cash burn
Operating cash use increased to $62.8 million in the six months ended June 30, 2026 from $53.5 million in the prior-year period. Management expects significant additional expenses and operating losses for at least the next several years.
-
Approval and commercialization dependency
Savara has no product revenue and stated it does not know when, or if, product revenue will begin. Revenue depends on regulatory approval and commercialization of MOLBREEVI, whose FDA action date was extended to November 22, 2026.
-
Potential need for additional capital
Management stated that additional capital may be needed to fund development, regulatory approvals and commercialization, despite approximately $173.0 million of cash, cash equivalents and short-term investments at June 30, 2026.
-
Development and manufacturing costs
Second-quarter research and development expense rose 5.8% year over year to $22.0 million, and management expects R&D spending to remain significant, including investment in a second-source manufacturer and CMC supplies.
-
Debt access depends on approval
The Hercules Loan Agreement provides for up to $105.0 million, but future tranches are subject to conditions including FDA approval; the facility carried an 8.2% interest rate at June 30, 2026.
Management's outlook
No explicit numeric revenue or EPS guidance was provided. Management stated it does not expect product revenue unless and until MOLBREEVI receives regulatory approval and is commercialized. The FDA PDUFA target action date is November 22, 2026, following a three-month extension.
Earlier filings 4
10-K · March 13, 2026
Savara Inc., a clinical-stage biopharmaceutical company focused on autoimmune pulmonary diseases, reported an operating loss of $123.5 million for the year ended December 31, 2025, an increase from $103.2 million in…
10-Q · November 12, 2025
Savara Inc. reported a net loss of $29.6 million for Q3 2025, an increase from the previous year's loss of $24.2 million, reflecting continued challenges with revenue generation as the company reported zero revenue.…
10-Q · August 13, 2025
Savara Inc. reported a net loss of $30.4 million for Q2 2025, an increase from $22.2 million in Q2 2024. The company continues to have no revenue, reflecting ongoing research and development costs primarily related to…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.